Abdelhadi Rebbaa on Senolytics

On Sunday, July 28, 2024, at 1 p.m. U.S. Pacific Time, the U.S. Transhumanist Party invites Dr. Abdelhadi Rebbaa to discuss his views regarding the potential and limitations for using senolytics to treat aging and go over alternative/complementary approaches to delay senescence onset. Dr. Abdelhadi Rebbaa received his PhD in Biochemistry from the Université Claude Bernard, Lyon, France. He held research and faculty positions at Northwestern University, the University of Pittsburgh, and Columbia University.  Over the course of his career, his research encompassed target and drug discovery and development in the fields of cancer, stem cells, and aging. He served as a Principal Investigator on multiple grants, published over 40 manuscripts, and reviewed manuscripts for several high-impact scientific journals. In his role at Ichor Therapeutics from 2018 to 2021, he oversaw the discovery and preclinical testing of small-molecule senolytics and biomarkers of aging. He then worked for SENS Research Foundation between January 2022 and January 2024, where his role was to conceive, design, and oversee research projects on senescence prevention, senolytics, and partial reprogramming. Now he works as a Project Management Consultant in New Jersey. See Dr. Abdelhadi Rebbaa’s LinkedIn profile: https://www.linkedin.com/in/abdelhadi-rebbaa-32bb9279/